OnCo
peoplePerson

Andrew Wardley

Andrew Wardley is a breast oncologist involved in the PERSEPHONE trial of shorter trastuzumab.

Andrew Wardley is a breast cancer trialist at The Christie who contributed to PERSEPHONE, the trial testing six versus twelve months of adjuvant trastuzumab.

Role
Consultant Medical Oncologist, The Christie; Honorary Professor, University of Manchester
Specialisms
Breast cancerHER2-positive diseaseAdjuvant trials
Profiles

Key papers

1top
rctJournal of Clinical Oncology 2020changed practice
monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer

Women with hormone-receptor-positive, HER2-negative breast cancer that has spread to lymph nodes and has other high-risk features can now be offered two years of abemaciclib alongside their hormone therapy, with a durable reduction in relapse. It does not apply to node-negative or low-risk disease, and the diarrhoea and cost are real trade-offs to discuss.

Connected

5top

cancers

1
HER2-positive breast cancer

drugs

1
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)

institutions

1
The Christie NHS Foundation Trust

trials

1
PERSEPHONE

key papers

1
monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer